Potent anti-cancer compound. Induces apoptosis in normal and tumor cell lines. DNA Topoisomerase II activity inhibitor. Increases Topo II-mediated DNA breakage primarily by inhibiting the ability of the enzyme to religate cleaved nucleic acid molecules. Does not lead to immediate block of DNS synthesis, induces a progressive inhibition of DNA replication. p53 activator. Blocks the cell cycle between the end of the S phase and the early G2 phase. Oncoprotein Mdm2 synthesis inhibitor. Apoptosis inducer through the cytochrome c/Apaf-1/caspase-9 pathway and the Fas-mediated death signaling pathway. Cell cycle checkpoint activator. Affects gene expression at different levels (chromatin remodeling, transcrip- tion and alternative splicing). Chemotherapeutic compound used in cancers. Used in conditioning regimen prior to a bone marrow or blood stem cell transplantation. Highly effective in mobilizing stem cells.Water (Karl Fischer): ≤ 6%Optical Rotation: [a]D20 = -110 to -118°Solubility:Very slightly soluble in water; slightly soluble in alcohol, in chloroform, in ethyl acetate, and in methylene chloride; sparingly soluble in methanol.Residue on Ignition:≤ 0.1%Heavy Metals:≤ 0.002%Residual Solvents:Ethanol: ≤ 0.5% Isopropyl Ether: ≤ 0.1% Ethyl acetate: ≤ 0.5% Dichloromethane: ≤ 0.06% Tetrahydrofuran: ≤ 0.072% Pyridine: ≤ 0.02% Methanol: ≤ 0.3% Ethyl ether: ≤ 0.5% Acetone: ≤ 0.5%Related Substances:Lignan P: ≤ 0.5% Picroetoposide: ≤ 1.0% All related compounds and impurities: ≤ 2%Storage and Stability:Lyophilized powder may be stored at 4°C. Stable for 6 months at 4°C.
